Figure 5.

Immune-related gene expressions in AKR tumors in early and late phases of the combination therapy

Expressions of the 12 genes in subcutaneous AKR tumors in an early phase (day 3) and a late phase (day 7) of the combination therapy. Comparisons of gene expressions related to (A−C) inflammation (Ccl5, Il1a, and Il1b), (D−F) lymphocytes (Cd4, Cd8a, and Foxp3), (G and H) Th1 response (Cxcl10 and Cxcr3), (I) Th2 response (Il2), (J) exhaustion marker (Cd274), and (K and L) T cell activation (Gzmb and Prf1). Top and bottom lines represent data on day 3 and day 7, respectively. The bar represents mean fold change + SEM (n = 6). One-way ANOVA followed by Dunnett’s test was used to determine statistical significance (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns, not significant).